Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 14751 - 14775 of 14991 in total

Sirna-027

Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1). VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. It is used to treat Macular...
Investigational
Matched Description: … Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. …

L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal

C-101, also called Myodur, is developed for the treatment of Duchenne’s muscular dystrophy (DMD) which is a morbid genetic disease that can lead to death in late adolescence due to accelerated skeletal muscle breakdown. C-101 includes a carnitine carrier molecule and a leupeptin analogue, a known calpain inhibitor. Calpain is...
Investigational
Matched Description: … C-101 includes a carnitine carrier molecule and a leupeptin analogue, a known calpain inhibitor. …

BW-A 58C

BW-A 58C, also known as 2-(4-tert-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone, is an experimental naphthoquinone antimalarial drug which undergoes extensive alkyl hydroxylation to a single t-butylhydroxy metabolite in man in vivo and also in human liver microsomes, where this is catalysed primarily by a 54 kDa CYP2C9 form of cytochrome P450, P450hB20-27.
Experimental
Matched Description: … which undergoes extensive alkyl hydroxylation to a single t-butylhydroxy metabolite in man in vivo and …

1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea

Experimental

1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea

Experimental

4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL

Experimental

2-(2-Hydroxy-5-Methoxy-Phenyl)-1h-Benzoimidazole-5-Carboxamidine

Experimental

6-fluoro-2-(2-hydroxy-3-isobutoxy-phenyl)-1H-benzoimidazole-5-carboxamidine

Experimental

(5S)-2-{[(1S)-1-(4-Fluorophenyl)ethyl]amino}-5-(2-hydroxy-2-propanyl)-5-methyl-1,3-thiazol-4(5H)-one

Experimental

4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol

Experimental

3-[6-bromo-2-fluoro-3-(1H-pyrazolo[3,4-c]pyridazin-3-ylmethyl)phenoxy]-5-chlorobenzonitrile

Experimental

CRA-9334

Experimental

Doramapimod

Doramapimod is a P38 MAP kinase inhibitor.
Investigational

(3R)-3-[(1,2,3,4-tetrahydroisoquinolin-7-yloxy)methyl]-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine

Experimental

4-(6-HYDROXY-BENZO[D]ISOXAZOL-3-YL)BENZENE-1,3-DIOL

Experimental

CCT-018159

Experimental

MK-4965

MK-4965 is an HIV-1 reverse transcriptase inhibitor.
Experimental

MRX-I

MRX-I has been used in trials studying the treatment of Bacterial Infections.
Investigational

6-amino-2-[(2-morpholin-4-ylethyl)amino]-3,7-dihydro-8H-imidazo[4,5-g]quinazolin-8-one

Experimental

N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine

Experimental

DG051

DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4...
Investigational
Matched Description: … attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and …

Alphamethadol

Experimental
Illicit

3-Amino-4-Oxybenzyl-2-Butanone

Experimental

Benzylamine

Experimental

1,3-Dinitrobenzene

Experimental
Displaying drugs 14751 - 14775 of 14991 in total